Overview Dividends

(ARWR) Arrowhead Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04280A1007

Plozasiran, Olpasiran, Fazirsiran, Zodasiran, Daplusiran

Biotechnology
Market Cap in USD: 9,372m
IPO / Inception: 1993-06-16
Return 12m vs S&P 500: 178%

EPS (Earnings per Share)

EPS (Earnings per Share) of ARWR over the last years for every Quarter: "2020-12": -0.2, "2021-03": -0.26, "2021-06": -0.29, "2021-09": -0.61, "2021-12": -0.6, "2022-03": 0.41, "2022-06": -0.68, "2022-09": -0.81, "2022-12": -0.39, "2023-03": 0.45, "2023-06": -0.96, "2023-09": -1.02, "2023-12": -1.24, "2024-03": -1.02, "2024-06": -1.38, "2024-09": -1.37, "2024-12": -1.39, "2025-03": 2.75, "2025-06": -1.26, "2025-09": -0.11, "2025-12": 0,
EPS CAGR: -6.28%
EPS Trend: 3.2%
Last SUE: -0.09
Qual. Beats: 0

Revenue

Revenue of ARWR over the last years for every Quarter: 2020-12: 21.303, 2021-03: 32.811, 2021-06: 45.891, 2021-09: 38.283, 2021-12: 27.439, 2022-03: 151.805, 2022-06: 32.412, 2022-09: 31.575, 2022-12: 62.546, 2023-03: 146.267, 2023-06: 15.825, 2023-09: 16.097, 2023-12: 3.551, 2024-03: 0, 2024-06: 0, 2024-09: 23.589, 2024-12: 2.5, 2025-03: 542.709, 2025-06: 27.767, 2025-09: 256.472, 2025-12: null,
Rev. CAGR: 81.49%
Rev. Trend: -9.4%
Last SUE: 0.44
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 72.7%
Value at Risk 5%th 108%
Relative Tail Risk -9.98%
Reward TTM
Sharpe Ratio 1.94
Alpha 206.12
CAGR/Max DD 0.29
Character TTM
Hurst Exponent 0.582
Beta 1.773
Beta Downside 1.590
Drawdowns 3y
Max DD 75.86%
Mean DD 34.96%
Median DD 35.63%

Description: ARWR Arrowhead Pharmaceuticals November 10, 2025

Arrowhead Pharmaceuticals (NASDAQ: ARWR) focuses on RNA-targeted medicines for hard-to-treat diseases. Its late-stage portfolio includes three Phase 3 candidates-Plozasiran (hypertriglyceridemia, dyslipidemia, familial chylomicronemia syndrome), Olpasiran (apo-A reduction) and Fazirsiran (alpha-1 antitrypsin-related liver disease)-plus a suite of Phase 2/1 programs targeting metabolic, hepatic, pulmonary and rare-disease indications. The company leverages a network of collaborations with GlaxoSmithKline, Horizon Therapeutics, Takeda and Amgen to co-develop and commercialize its RNAi platform.

As of the most recent filing, Arrowhead reported a market capitalization of roughly $2.5 billion and cash and equivalents of $300 million, giving it an estimated 12-month runway at current burn rates (~$200 million FY 2023 R&D spend). The biotech sector’s revenue growth is projected at a 10 % CAGR through 2029, driven by expanding demand for gene-silencing therapeutics and favorable reimbursement trends for rare-disease treatments-factors that could amplify ARWR’s upside if its Phase 3 readouts meet primary endpoints.

For a deeper dive into Arrowhead’s valuation metrics and scenario analysis, you might find the research tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (-1.63m TTM) > 0 and > 6% of Revenue (6% = 49.8m TTM)
FCFTA 0.11 (>2.0%) and ΔFCFTA 64.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 91.04% (prev 2182 %; Δ -2091 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.13 (>3.0%) and CFO 179.6m > Net Income -1.63m (YES >=105%, WARN >=100%)
Net Debt (166.2m) to EBITDA (100.6m) ratio: 1.65 <= 3.0 (WARN <= 3.5)
Current Ratio 4.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (135.7m) change vs 12m ago 11.24% (target <= -2.0% for YES)
Gross Margin 97.89% (prev 0.0%; Δ 97.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 65.70% (prev 2.38%; Δ 63.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.93 (EBITDA TTM 100.6m / Interest Expense TTM 89.4m) >= 6 (WARN >= 3)

Altman Z'' -1.75

(A) 0.55 = (Total Current Assets 950.6m - Total Current Liabilities 195.5m) / Total Assets 1.39b
(B) -1.17 = Retained Earnings (Balance) -1.63b / Total Assets 1.39b
warn (B) unusual magnitude: -1.17 — check mapping/units
(C) 0.07 = EBIT TTM 83.1m / Avg Total Assets 1.26b
(D) -1.85 = Book Value of Equity -1.63b / Total Liabilities 881.9m
Total Rating: -1.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 49.17

1. Piotroski 5.50pt
2. FCF Yield 1.57%
3. FCF Margin 18.91%
4. Debt/Equity 1.57
5. Debt/Ebitda 1.65
6. ROIC - WACC (= -6.63)%
7. RoE -0.38%
8. Rev. Trend -9.36%
9. EPS Trend 3.19%

What is the price of ARWR shares?

As of January 09, 2026, the stock is trading at USD 65.00 with a total of 6,958,015 shares traded.
Over the past week, the price has changed by -4.12%, over one month by -5.25%, over three months by +75.96% and over the past year by +229.11%.

Is ARWR a buy, sell or hold?

Arrowhead Pharmaceuticals has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ARWR.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 5
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ARWR price?

Issuer Target Up/Down from current
Wallstreet Target Price 67.5 3.8%
Analysts Target Price 67.5 3.8%
ValueRay Target Price 69.3 6.6%

ARWR Fundamental Data Overview January 03, 2026

P/E Forward = 111.1111
P/S = 11.2997
P/B = 19.3463
P/EG = -1.32
Beta = 1.288
Revenue TTM = 829.4m USD
EBIT TTM = 83.1m USD
EBITDA TTM = 100.6m USD
Long Term Debt = 214.9m USD (from longTermDebt, last quarter)
Short Term Debt = 40.0m USD (from shortLongTermDebt, last quarter)
Debt = 733.7m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 166.2m USD (from netDebt column, last quarter)
Enterprise Value = 10.02b USD (9.37b + Debt 733.7m - CCE 88.7m)
Interest Coverage Ratio = 0.93 (Ebit TTM 83.1m / Interest Expense TTM 89.4m)
FCF Yield = 1.57% (FCF TTM 156.9m / Enterprise Value 10.02b)
FCF Margin = 18.91% (FCF TTM 156.9m / Revenue TTM 829.4m)
Net Margin = -0.20% (Net Income TTM -1.63m / Revenue TTM 829.4m)
Gross Margin = 97.89% ((Revenue TTM 829.4m - Cost of Revenue TTM 17.5m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 77.59%)
Tobins Q-Ratio = 7.23 (Enterprise Value 10.02b / Total Assets 1.39b)
Interest Expense / Debt = 2.96% (Interest Expense 21.7m / Debt 733.7m)
Taxrate = 55.37% (20.0m / 36.1m)
NOPAT = 37.1m (EBIT 83.1m * (1 - 55.37%))
Current Ratio = 4.86 (Total Current Assets 950.6m / Total Current Liabilities 195.5m)
Debt / Equity = 1.57 (Debt 733.7m / totalStockholderEquity, last quarter 466.1m)
Debt / EBITDA = 1.65 (Net Debt 166.2m / EBITDA 100.6m)
Debt / FCF = 1.06 (Net Debt 166.2m / FCF TTM 156.9m)
Total Stockholder Equity = 431.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.13% (Net Income -1.63m / Total Assets 1.39b)
RoE = -0.38% (Net Income TTM -1.63m / Total Stockholder Equity 431.1m)
RoCE = 12.86% (EBIT 83.1m / Capital Employed (Equity 431.1m + L.T.Debt 214.9m))
RoIC = 5.11% (NOPAT 37.1m / Invested Capital 725.7m)
WACC = 11.73% (E(9.37b)/V(10.11b) * Re(12.55%) + D(733.7m)/V(10.11b) * Rd(2.96%) * (1-Tc(0.55)))
Discount Rate = 12.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.40%
[DCF Debug] Terminal Value 70.38% ; FCFF base≈156.9m ; Y1≈193.5m ; Y5≈330.2m
Fair Price DCF = 22.17 (EV 3.18b - Net Debt 166.2m = Equity 3.01b / Shares 135.8m; r=11.73% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 3.19 | EPS CAGR: -6.28% | SUE: -0.09 | # QB: 0
Revenue Correlation: -9.36 | Revenue CAGR: 81.49% | SUE: 0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.08 | Chg30d=-0.343 | Revisions Net=-3 | Analysts=7
EPS current Year (2026-09-30): EPS=-3.16 | Chg30d=-0.040 | Revisions Net=-4 | Growth EPS=-31536.4% | Growth Revenue=-50.0%
EPS next Year (2027-09-30): EPS=-4.53 | Chg30d=-0.589 | Revisions Net=-4 | Growth EPS=-43.0% | Growth Revenue=-33.6%

Additional Sources for ARWR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle